Bicara Therapeutics (NASDAQ:BCAX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Bicara Therapeutics (NASDAQ:BCAX) had its target price boosted by stock analysts at HC Wainwright from $42.00 to $45.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 287.93% from the company’s previous close.

Several other equities research analysts have also commented on BCAX. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective for the company. TD Cowen began coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating for the company. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Finally, Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $43.75.

Bicara Therapeutics Price Performance

BCAX stock opened at $11.60 on Monday. Bicara Therapeutics has a 52-week low of $11.51 and a 52-week high of $28.09. The company’s 50-day moving average is $17.08.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. purchased a new position in shares of Bicara Therapeutics in the 3rd quarter worth about $177,169,000. FMR LLC purchased a new position in shares of Bicara Therapeutics during the third quarter worth approximately $57,913,000. Braidwell LP bought a new stake in shares of Bicara Therapeutics in the 3rd quarter worth approximately $42,219,000. Janus Henderson Group PLC purchased a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at $30,329,000. Finally, Baker BROS. Advisors LP purchased a new position in Bicara Therapeutics in the 3rd quarter worth $21,225,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.